Sensei Biotherapeutics (NASDAQ:FTH) Trading Down 5.5% - Here's What Happened

Key Points

• Sensei Biotherapeutics shares fell 5.5% to about $32.59, with trading volume down 69% from its average daily level.
• Analysts remain broadly optimistic, with a consensus rating of “Moderate Buy” and an average price target of $56.25; recent targets range from $51 to $70.
• The company reported a quarterly loss of $2.84 per share, beating estimates by $2.20, while insiders purchased 38,505 shares worth approximately $952,285 over the past 90 days.

Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report)'s share price fell 5.5% on Monday . The stock traded as low as $32.38 and last traded at $32.5860. 72,708 shares changed hands during trading, a decline of 69% from the average daily volume of 230,977 shares. The stock had previously closed at $34.50.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. BTIG Research reaffirmed a "buy" rating and set a $55.00 target price on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Needham & Company LLC initiated coverage on Sensei Biotherapeutics in a research note on Friday, August 21st. They set a "buy" rating and a $56.00 price objective for the company. Guggenheim assumed coverage on Sensei Biotherapeutics in a report on Wednesday, September 16th. They set a "buy" rating and a $70.00 price objective on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Finally, Citizens Jmp initiated coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an "outperform" rating and a $51.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $56.25.

Sensei Biotherapeutics Stock Performance

The firm's 50 day moving average price is $31.96. The company has a market cap of $838.25 million, a price-to-earnings ratio of -0.23 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($5.04) by $2.20. Equities research analysts forecast that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current year.

Insider Buying and Selling at Sensei Biotherapeutics

In other news, CFO Brian C. Stephenson purchased 5,000 shares of the company's stock in a transaction that occurred on Wednesday, July 1st. The shares were acquired at an average cost of $23.50 per share, with a total value of $117,500.00. Following the transaction, the chief financial officer owned 46,688 shares in the company, valued at approximately $1,097,168. The trade was a 11.99% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders purchased 38,505 shares of company stock valued at $952,285. 7.00% of the stock is currently owned by insiders.

Institutional Trading of Sensei Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of FTH. Citadel Advisors LLC acquired a new position in shares of Sensei Biotherapeutics in the 2nd quarter valued at about $307,000. Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the second quarter worth about $3,610,000. Vivo Capital LLC bought a new position in Sensei Biotherapeutics in the first quarter worth about $22,758,000. Bank of America Corp DE lifted its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after acquiring an additional 32,719 shares during the last quarter. Finally, Stempoint Capital LP acquired a new position in Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei's technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.